Quick Facts
Plain-English Summary
Pinealon is a synthetic tripeptide consisting of three amino acids — glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg) — developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to a family of short peptide bioregulators identified through the isolation and fractionation of tissue-specific extracts from various organs. Pinealon is the pineal gland-specific member of this series; Epithalon (another Khavinson peptide) targets pineal telomerase activity, while Thymagen targets thymic function. The three compounds are often discussed together within the Khavinson research program.
The compound is hypothesised to act on pineal gland function, with proposed effects including modulation of melatonin synthesis, circadian rhythm signalling, and antioxidant activity in neural tissue. Animal model research has demonstrated neuroprotective effects under conditions of oxidative stress and hypoxia-induced neuronal injury, with putative mechanisms involving upregulation of endogenous antioxidant enzymes — superoxide dismutase (SOD) and catalase — in brain tissue. In vitro antioxidant activity has also been reported.
Human data is limited and methodologically modest. Published studies examining cognitive parameters in elderly cohorts have been conducted, primarily by the Khavinson group, and report improvements in cognitive measures and subjective wellbeing in aging populations. These studies are generally small, lack independent replication, and do not meet contemporary standards for controlled clinical evidence. As with other Khavinson bioregulators, the research program is productive but concentrated within a single institution.
The entirety of published Pinealon research originates from or is closely affiliated with the St. Petersburg Institute of Bioregulation and Gerontology (V.Kh. Khavinson's group). Independent replication by unaffiliated institutions is absent from the current literature — a critical limitation that constrains confidence in the evidence base.
The biohacker community's interest in Pinealon centres primarily on sleep regulation and anti-aging via the melatonin and pineal pathway. Community discussion is more subdued than for higher-profile Khavinson peptides such as Epithalon. Claims circulating in vendor and influencer channels — including restoration of youthful sleep, reversal of age-related cognitive decline, and life extension — are not supported by the existing preclinical and small-scale human data.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Rat cerebral hypoxia | Reduced neuronal death in cortical and hippocampal tissue following hypoxic insult. Effect attributed to attenuation of oxidative stress markers. Linkova NS et al. ↗ | Preclinical |
| Rodent oxidative stress model | Increased SOD and catalase activity in brain homogenates of Pinealon-treated animals vs. controls. Reduction in lipid peroxidation markers (MDA) also reported. Khavinson VKh et al. ↗ | Preclinical |
| In vitro antioxidant (neural cell lines) | Dose-dependent reduction in ROS generation in neuronal cell cultures exposed to hydrogen peroxide challenge. Direct chemical antioxidant capacity not fully separated from gene-regulatory effects. | Preclinical |
| Aged rat cognitive model | Modest improvement in maze performance and spatial memory tasks in aged rodents. Effect size smaller and less consistent than Epithalon data from the same research group. | Preclinical |
| Rat pineal gland histology | Observed structural changes in pinealocyte morphology consistent with peptide bioregulator interaction. Functional significance of histological changes was not directly assessed. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Observational — Elderly Cognitive Parameters | Small cohort of elderly subjects; cognitive and psychometric assessments pre/post Pinealon administration | — | Incomplete |
| All registered RCTs | — | — | No Data |
Pinealon has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
No significant acute toxicity reported in rodent studies at doses used in research. As a short tripeptide, Pinealon is expected to have a relatively benign proteolytic degradation profile. However, formal toxicology studies (genotoxicity, carcinogenicity, chronic dosing) have not been published in the open literature.
Compounds that modulate melatonin pathway activity or circadian signalling could theoretically interact with existing hormonal conditions, mood disorders, or immunological states. Any agent affecting pineal function warrants caution in individuals with hormone-sensitive conditions or psychiatric diagnoses. No human adverse event data exists for Pinealon.
- Altered sleep onset or sleep depth (reported variably)
- Vivid or unusual dreams
- Injection site mild soreness
- Transient fatigue on initiation
- No pharmacovigilance database exists for Pinealon
- Active or suspected malignancy
- Pregnancy or breastfeeding
- Hormone-sensitive conditions
- Existing sleep or circadian disorder under medical treatment
- Psychiatric conditions (bipolar, schizophrenia)
- Children and adolescents
Pinealon is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Pinealon for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
The Khavinson group's framing is interesting and internally consistent, but it creates an interpretive problem: almost everything they publish on these peptides is designed to support the tissue-specific bioregulator hypothesis from the outset. Pinealon is derived by fractionating pineal extract, and then it's studied primarily in assays that are expected to reflect pineal function. That's not automatically wrong, but it makes independent replication essential and it's essentially absent. What I'd want to see is a group with no stake in the hypothesis running the same oxidative stress assays with the EDR tripeptide and reporting results regardless of outcome.
The SOD/catalase upregulation data is at least plausible at the molecular level — short peptides can modulate transcription factor activity through mechanisms that aren't fully elucidated. The problem is distinguishing a genuine gene-regulatory effect from non-specific stress response. Any exogenous peptide can trigger a stress-response upregulation of antioxidant enzymes. The Khavinson papers don't always rule out that confound cleanly.
People stacking Pinealon primarily for sleep are mostly operating on theoretical grounds. The melatonin pathway connection is intuitive — if the compound is derived from pineal tissue and is proposed to act on pinealocyte function, it seems reasonable that sleep architecture could be affected. But the actual sleep-outcome data doesn't exist in any meaningful controlled form. What gets reported anecdotally is a lot of vivid dreaming and altered sleep depth, which could be placebo, could be a real effect on melatonin timing, or could be downstream of the antioxidant activity on neural tissue generally. Those three explanations lead to very different conclusions about how to use the compound.
Comparing it to Epithalon: Epithalon has a meaningful body of animal telomerase data and some controlled human data, which makes it a stronger scientific candidate even if it's still preclinical. Pinealon has a narrower evidence profile — the neuroprotection angle is real but thin, and the melatonin hypothesis is mostly inferential. If someone is choosing within the Khavinson peptide family specifically for cognitive longevity or neuroprotection, the evidence hierarchy currently points to Epithalon over Pinealon. Pinealon might turn out to have a complementary mechanism, but the data doesn't establish that yet.
That's accurate. The Khavinson framework positions these peptides as organ-specific regulators intended to be used in parallel, not in isolation. Whether combinatorial use adds anything meaningful over individual compounds is completely untested. The marketing stacks them; the science doesn't validate the stack.
The human data that does exist is in elderly Russian cohorts studied in the 1990s and 2000s, reporting cognitive parameter improvements. Setting aside the replication problem, these were observational studies without blinding, often using composite subjective endpoints. The effect sizes reported look plausible but the methodology doesn't support confidence. As a tripeptide, Pinealon is likely to have better oral bioavailability than longer peptides simply due to size — but nobody has actually measured plasma levels after any route of administration in humans. The standard problem: Russian preclinical literature that's intriguing but structurally isolated from the international trial infrastructure that would test it properly.